Semaglutide is a weight loss drug that targets the glucagon-like peptide-1 (GLP-1), sold by Novo Nordisk under the brand name Wegovy to treat people with obesity and under Ozempic to treat patients with both type 2 diabetes and obesity
[1] Injection site reactions occur when the body responds to the physical trauma of needle insertion, the medication itself, or both
There is a long list of drugs and drug classes known to cause temporary hair loss from telogen effluvium
These properties affect the stability and targeting efficiency of the NPs in a biological environment and can either hamper or improve the delivery of therapeutics to bacterial cells [198]
The most common side effect is a temporary increase in pain at the injection site once the local anaesthetic wears off, often referred to as a 'steroid flare'
GLP-1 drugs are associated with a higher risk of wet age-related macular degeneration in people with type 2 diabetes, according to a new study